{
  "id": 13696144,
  "title": "Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock",
  "url": "https://urgent.news/2026/10/11/ligand-pharma-clo-andrew-reardon-sells-1-52-million-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-11T10:31:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/ligand-pharma-clo-andrew-reardon-sells-152-million-in-stock-93CH-4942581"
  },
  "original_language": "en",
  "account": null,
  "summary": "Ligand Pharmaceuticals Inc. (LGND) saw Chief Legal Officer and Secretary Andrew Reardon sell 5,000 shares of common stock on October 2, 2026, for a total of $1.52 million, as per a pre-arranged Rule 10b5-1 trading plan adopted in June 2026. This comes amid a 70% surge in LGND's shares over the past year, currently trading near $302. Reardon also exercised employee stock options, acquiring an additional 340 shares. Meanwhile, Ligand reported strong Q2 2026 results with adjusted earnings of $2.37 per share and revenue exceeding $83.7 million, surpassing analyst projections. The company's strategic moves, including a 32% increase in royalty revenue and recent financing deals, highlight its evolving business strategy and financial strength.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}